Virax Biolabs Group Limited
NASDAQ: VRAX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Foster
- Employees
- 19
- Headquarters
- Lanarkshire, United Kingdom
- IPO year
- 2022
- Market cap
- $511.4K
- Website
- https://viraxbiolabs.com
Loading VRAX…
Loading profile data…Frequently asked questions about VRAX
What does Virax Biolabs Group Limited (VRAX) do?
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chron...
Where does VRAX trade?
Virax Biolabs Group Limited (VRAX) trades on the NASDAQ.
What sector is VRAX in?
Virax Biolabs Group Limited (VRAX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Virax Biolabs Group Limited?
James Foster is the chief executive officer of Virax Biolabs Group Limited (VRAX).
Where is Virax Biolabs Group Limited headquartered?
Virax Biolabs Group Limited is headquartered in United Kingdom.
Does VRAX pay a dividend?
Virax Biolabs Group Limited (VRAX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VRAX go public?
Virax Biolabs Group Limited (VRAX) completed its initial public offering in 2022.